Our study provides another promising strategy to treat the peripheral neuropathy resulting from CMT by inhibiting SIRT2, suggesting that the targeting of SIRT2 might have a general beneficial impact on neurodegenerative diseases. This evidence concerns the gene SIRT2 and Charcot-Marie-Tooth disease.